Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints

Executive Summary

Merck's Keytruda gains huge advantage in first-line lung cancer as Bristol's stumble in patients with lower expression of PD-L-1 biomarker raises questions about cut-off levels in trials.

You may also be interested in...



Tumor Mutation Burden Biomarker Emerges In Bristol's '026 Lung Cancer Post Mortem

Bristol says it's too early to make predictions for future immunotherapy regimens based on new tumor mutation burden analysis of the failed Opdivo Checkmate 026 trial aired at the AACR meeting, but the company plans to fully explore this important biomarker.

Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer

The latest drug development news and highlights from our FDA Performance Tracker.

Medivation Sees Potential For Combinations Out Of Opdivo Failure

Failure of Bristol's PD-1 inhibitor Opdivo in first-line lung cancer may open doors for combination use with drugs with immune-activating properties, like prostate cancer drug Xtandi and PARP inhibitor talazoparib.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS118916

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel